FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Kath

Research Profile

Chemicals & Drugs

Phenomena

Phosphorylation

Procedures

Xenograft Model Antitumor Assays

Living Beings

Disorders

Breast Neoplasms

Physiology

Anatomy

Cell Line

Concepts & Ideas

Inhibitory Concentration 50

Co-author Network

Publications

TOP 3
Daniel P Walker; F Christopher Bi; Amit S Kalgutkar; Jonathan N Bauman; Sabrina X Zhao; John R Soglia; Gary E Aspnes; Daniel W Kung; Jacquelyn Klug-McLeod; Michael P Zawistoski; Molly A McGlynn; Robert Oliver; Matthew Dunn; Jian-Cheng Li; Daniel T Richter; Beth A Cooper; John C Kath; Catherine A Hulford; Christopher L Autry; Michael J Luzzio; Ethan J Ung; W Gregory Roberts; Peter C Bonnette; Leonard Buckbinder; Anil Mistry; Matthew C Griffor; Seungil Han; Angel Guzman-Perez
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
Jitesh P Jani; Richard S Finn; Mary Campbell; Kevin G Coleman; Richard D Connell; Nicolas Currier; Erling Emerson; Eugenia Floyd; Shawn Harriman; John C Kath; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Sherry Ralston; Ann Marie K Rossi; Salome Steyn; Larry Wagner; Steven M Winter; Samit K Bhattacharya
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Leonard Buckbinder; D Todd Crawford; Hong Qi; Hua Zhu Ke; Lisa M Olson; Kelly R Long; Peter C Bonnette; Amy P Baumann; John E Hambor; William A Grasser; Lydia C Pan; Thomas A Owen; Michael J Luzzio; Catherine A Hulford; David F Gebhard; Vishwas M Paralkar; Hollis A Simmons; John C Kath; W Gregory Roberts; Steven L Smock; Angel Guzman-Perez; Thomas Brown; Mei Li
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Kath (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Daniel P Walker; F Christopher Bi; Amit S Kalgutkar; Jonathan N Bauman; Sabrina X Zhao; John R Soglia; Gary E Aspnes; Daniel W Kung; Jacquelyn Klug-McLeod; Michael P Zawistoski; Molly A McGlynn; Robert Oliver; Matthew Dunn; Jian-Cheng Li; Daniel T Richter; Beth A Cooper; John C Kath; Catherine A Hulford; Christopher L Autry; Michael J Luzzio; Ethan J Ung; W Gregory Roberts; Peter C Bonnette; Leonard Buckbinder; Anil Mistry; Matthew C Griffor; Seungil Han; Angel Guzman-Perez
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
Bioorganic & medicinal chemistry letters 2008;18(23):6071-7.
2007: Jitesh P Jani; Richard S Finn; Mary Campbell; Kevin G Coleman; Richard D Connell; Nicolas Currier; Erling Emerson; Eugenia Floyd; Shawn Harriman; John C Kath; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Sherry Ralston; Ann Marie K Rossi; Salome Steyn; Larry Wagner; Steven M Winter; Samit K Bhattacharya
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Cancer research 2007;67(20):9887-93.
2007: Leonard Buckbinder; D Todd Crawford; Hong Qi; Hua Zhu Ke; Lisa M Olson; Kelly R Long; Peter C Bonnette; Amy P Baumann; John E Hambor; William A Grasser; Lydia C Pan; Thomas A Owen; Michael J Luzzio; Catherine A Hulford; David F Gebhard; Vishwas M Paralkar; Hollis A Simmons; John C Kath; W Gregory Roberts; Steven L Smock; Angel Guzman-Perez; Thomas Brown; Mei Li
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(25):10619-24.
2007: Jill K Slack-Davis; Karen H Martin; Robert W Tilghman; Marcin Iwanicki; Ethan J Ung; Christopher Autry; Michael J Luzzio; Beth Cooper; John C Kath; W Gregory Roberts; Thomas J Parsons
Cellular characterization of a novel focal adhesion kinase inhibitor.
The Journal of biological chemistry 2007;282(20):14845-52.
2005: W Gregory Roberts; Pamela M Whalen; Erik Soderstrom; Garrett Moraski; Joseph P Lyssikatos; Huifen-F Wang; Beth Cooper; Deborah A Baker; Douglas Savage; Deepak K Dalvie; James A Atherton; Sherry Ralston; Ruby Szewc; John C Kath; Jing Lin; Cathy Soderstrom; George Tkalcevic; Bruce D Cohen; Vince Pollack; Wayne Barth; Will Hungerford; Ethan Ung
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Cancer research 2005;65(3):957-66.
2004: Matthew F Brown; Mike Avery; William H Brissette; J H Chang; Kevin Colizza; Maryrose Conklyn; Amy P DiRico; Ronald P Gladue; John C Kath; Suzanne S Krueger; Paul D Lira; Brett M Lillie; Greg D Lundquist; Erin N Mairs; Eric B McElroy; Molly A McGlynn; Timothy J Paradis; Christopher S Poss; Michelle I Rossulek; Richard M Shepard; Jeff Sims; Timothy J Strelevitz; Susan Truesdell; Laurie A Tylaska; Kwansik Yoon; Deye Zheng
Novel CCR1 antagonists with improved metabolic stability.
Bioorganic & medicinal chemistry letters 2004;14(9):2175-9.
2004: John C Kath; William H Brissette; Matthew F Brown; Maryrose Conklyn; Amy P DiRico; Peter Dorff; Ronald P Gladue; Brett M Lillie; Paul D Lira; Erin N Mairs; William Martin; Eric B McElroy; Molly A McGlynn; Timothy J Paradis; Christopher S Poss; Ingrid A Stock; Laurie A Tylaska; Deye Zheng
Potent small molecule CCR1 antagonists.
Bioorganic & medicinal chemistry letters 2004;14(9):2169-73.
2004: John C Kath; Amy P DiRico; Ronald P Gladue; William Martin; Eric B McElroy; Ingrid A Stock; Laurie A Tylaska; Deye Zheng
The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.
Bioorganic & medicinal chemistry letters 2004;14(9):2163-7.
2003: Ronald P Gladue; Laurie A Tylaska; William H Brissette; Paul D Lira; John C Kath; Christopher S Poss; Matthew F Brown; Timothy J Paradis; Maryrose Conklyn; Kevin Ogborne; Molly A McGlynn; Brett M Lillie; Amy P DiRico; Erin N Mairs; Eric B McElroy; William Martin; Ingrid A Stock; Richard M Shepard; Henry J Showell; Kuldeep S Neote
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases.
The Journal of biological chemistry 2003;278(42):40473-80.
2003: E Gabriella Barbacci; Leslie R Pustilnik; Ann Marie K Rossi; Erling Emerson; Penny E Miller; Brian P Boscoe; Eric D Cox; Kenneth K Iwata; Jitesh P Jani; Kathleen Provoncha; John C Kath; Zhengyu Liu; James D Moyer
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
Cancer research 2003;63(15):4450-9.
2003: Samit K Bhattacharya; Eric D Cox; John C Kath; Alan M Mathiowetz; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Daniel T Richter; Chunyan Su; Matthew D Wessel
Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Biochemical and biophysical research communications 2003;307(2):267-73.